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It is not uncommon for a pharmaceutical company to
develop several new drugs simultaneously for the same
indication. In a small population it may be infeasible to
try all new drugs concurrently. A practical approach is
to consider one at a time and if the drug is recom-
mended for a phase III trial to temporarily suspend
development of other drugs.
We propose a development plan that encompasses
phase II and III trials, considering a series of sequential
phase II trials with interim decision-making. At each
stage of a phase II trial, a decision is made whether to
continue with participant recruitment to the current
trial, stop the current trial and recommend the drug to
be tried in a phase III trial, stop the current trial and
initiate a new phase II trial with a different drug or stop
the current trial and abandon the development.
The unknown treatment effect for each drug is
assumed to follow a prior distribution. In addition, as
drugs are intended for the same population it is not
unrealistic to consider treatment effects to be correlated,
so that the prior distribution will reflect this. As data
are observed from preceding and current trials, prior
densities for subsequent drugs are updated, informing
us of the performance of the groups of drugs under eva-
luation. The application of the design is illustrated in
the setting of severe arthritis of the hip trials.
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